Is there a role for checkpoint inhibition in patients with advanced, high PD-L1 expressing, chemotherapy-refractory thymoma?  

What if the patient has thymoma-associated myasthenia gravis?



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution